<![CDATA[Cervical cancer is one of the most common malignancies affecting women and chemotherapy remains an important component of treatment, particularly in advanced or metastatic disease. Chemotherapy-induced nausea and vomiting (CINV) is one of the common adverse effects of chemotherapy that may interfere with nutritional status, hydration, treatment adherence, and quality of life. Appropriate antiemetic therapy is therefore important to support chemotherapy treatment. This study aimed to evaluate the use of antiemetic drugs in cervical cancer patients undergoing chemotherapy at Dr. M. Yunus Hospital, Bengkulu, during 2022–2024. This study used a non-experimental descriptive design with a retrospective approach. Data were obtained from medical records of cervical cancer patients receiving chemotherapy and antiemetic therapy. A total of 75 patients met the inclusion criteria and were evaluated based on patient characteristics, chemotherapy regimens, antiemetic use, and appropriateness of patient, indication, drug, dose, and administration route. The results showed that most patients were aged 51–60 years (37.33%), housewives (70.67%), had senior high school education (66.67%), and were diagnosed with stage IIIB cervical cancer (61.33%). The most frequently used chemotherapy regimen was paclitaxel plus carboplatin (86.67%), while the most commonly administered antiemetic regimen was ondansetron plus dexamethasone (57.33%). Evaluation demonstrated 100% appropriateness for patient, indication, drug, dose, and administration route. These findings indicate that antiemetic use at Dr. M. Yunus Hospital was rational based on the therapeutic guideline used in the study. Periodic evaluation is recommended to maintain the quality and appropriateness of antiemetic therapy.]]>
